March 08, 2023
bioMérieux 2022 Financial Results
bioMérieux announced a strong performance in 2022 with robust full-year sales at €3,589 million with a reported growth of +6.3% and an almost neutral organic growth of +0.2%.
Media & Press relations
Our latest press releases
Swipe for more
-
March 10, 2023
BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEAL™ Rapid AST System
BioFire Defense, LLC, has received a contract from the BARDA (Biomedical Advanced Research and Development Authority) to accelerate development of the Specific Diagnostics SPECIFIC REVEAL™ Rapid AST System that can deliver phenotypic results in an average of five and a half hours from positive blood cultures.
-
February 08, 2023
US FDA 510(k) Clearance and CLIA-waiver for the fast and innovative BIOFIRE® SPOTFIRE® System
bioMérieux receives US FDA 510(k) Clearance and CLIA-waiver for the fast and innovative BIOFIRE® SPOTFIRE® System and its BIOFIRE® SPOTFIRE® Respiratory (R) Panel and will be submitting the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini for 510(k) clearance.
-
February 01, 2023
MAESTRIA™, a new generation microbiology middleware developed by bioMérieux
bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIA™. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.
Media contacts
Olivier Rescanière
Phone: (+33) (0)4 78 87 20 00
Email: media@biomerieux.com
_____
Romain Duchez
Phone: (+33) (0)4 78 87 20 00
Email: media@biomerieux.com
